- Home
- ETON vs JANX Comparison
ETON vs JANX Comparison
Compare ETON & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ETON | JANX |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.7M | 984.3M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ETON | JANX |
|---|---|---|
| Price | $37.07 | $15.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 13 |
| Target Price | $39.33 | ★ $47.00 |
| AVG Volume (30 Days) | 406.6K | ★ 1.5M |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $79,950,000.00 | $10,000,000.00 |
| Revenue This Year | $40.90 | N/A |
| Revenue Next Year | $47.23 | N/A |
| P/E Ratio | $741.40 | ★ N/A |
| Revenue Growth | ★ 104.94 | N/A |
| 52 Week Low | $13.78 | $12.12 |
| 52 Week High | $39.48 | $35.34 |
Technical Indicators
Market Signals| Indicator | ETON | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 59.36 | 56.72 |
| Support Level | $15.77 | $13.13 |
| Resistance Level | $38.62 | $16.75 |
| Average True Range (ATR) | 1.59 | 0.65 |
| MACD | -0.14 | -0.01 |
| Stochastic Oscillator | 47.95 | 52.39 |
Price Performance
Historical ComparisonAbout ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.